Valneva's Stock Rises 3.14% at Close, Driven by Technical Interest Ahead of Crucial Phase 3 Results

Valneva's stock closed on Monday, December 22, at 3.676 euros, up 3.14% from the previous day's 3.56 euros. Trading volumes remained moderate with 0.26% of the capital traded during the session, reflecting reduced activity typical of this end-of-year period. Over the week, however, the stock has seen a slight decline of 1.45%, continuing the consolidation phase that began in early December after the announcement of positive Phase 2 results for the chikungunya vaccine in children on December 11. The past quarter has seen a decrease of 15.14%, indicative of the persistent volatility characteristic of the biotechnology sector. Over the year, performance remains impressive with a surge of 91.06%, primarily driven by advancements in the VLA15 program against Lyme disease. Technically, the price is currently below its 50-day moving average set at 3.92 euros but remains firmly above the 200-day moving average at 3.46 euros, confirming an underlying bullish trend despite short-term turbulence. The RSI is at 33, a level close to the oversold zone suggesting a potential for technical rebound, which could explain the rebound observed this Monday. The technical support identified at 3.49 euros has been tested several times in recent days and appears to hold, indicating sustained investor interest at these levels.

Interest in Valneva centers around VLA15, a vaccine candidate against Lyme disease developed in partnership with Pfizer. This program currently represents the only active vaccine in advanced clinical development against this disease, which affects about 476,000 people annually in the United States and 130,000 in Europe. The Phase 3 VALOR trial, which has enrolled over 9,400 participants aged five and older in endemic areas in the United States, Canada, and Europe, is expected to deliver its first results by the end of 2025. Pfizer plans to submit a marketing authorization application to the U.S. FDA and the European Medicines Agency in 2026, subject to positive data. This timeline partly explains the recent nervousness of the stock and the technical interest resurgence observed this Monday, as investors anticipate a major catalyst in the coming weeks. On November 26, Valneva announced positive final results from a Phase 2 study on VLA15, demonstrating a strong immune response six months after the third booster dose, which had propelled the stock up 6.92% during the session. The consensus among analysts remains constructive with an average target of 6.35 euros according to available data, representing a potential upside of nearly 73% from the current price of 3.676 euros. However, Goldman Sachs maintains a neutral recommendation with a lowered target of 3.25 euros as of November 28, reflecting short-term caution after the strong performance recorded in 2025.

The Franco-Austrian laboratory reported revenues of 127 million euros for the first nine months of 2025, up 8.9% compared to the same period the previous year. However, this growth comes in a context marked by the FDA's suspension in November of the license for IXCHIQ, its chikungunya vaccine intended for travelers. This decision led the company to revise its annual sales targets downward, now expected between 155 and 170 million euros, compared to an initial range of 170 to 180 million euros. The adjusted EBITDA remains negative at -37.7 million euros over nine months, reflecting sustained investments in research and development estimated between 80 and 90 million euros for the full year. To enhance operational efficiency, Valneva announced at the end of November the closure of its historical site in Nantes-Saint-Herblain and the transfer of all its French activities to Lyon, where the new headquarters will be established, while R&D will be centralized in Vienna, Austria. From a technical perspective, the MACD indicator displays a line at -0.08 and a signal line at -0.05, with a negative histogram at -0.03, indicating a still fragile but gradually improving dynamic. The one-month volatility stands at 14.44%, characteristic of biotechnology stocks awaiting major catalysts. The major resistance is at 4.30 euros, a level reached at the end of November and which will be a key technical threshold to validate a sustainable recovery of bullish momentum.